<DOC>
	<DOCNO>NCT02161718</DOCNO>
	<brief_summary>This double-blind , randomize study evaluate efficacy , safety tolerability ALKS 3831 subject schizophrenia alcohol use disorder ( AUD ) .</brief_summary>
	<brief_title>A Study ALKS 3831 Subjects With Schizophrenia Alcohol Use Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Has BMI 18.0 40.0 kg/m2 , inclusive Has diagnosis schizophrenia Has diagnosis alcohol use disorder ( AUD ) Has experience acute exacerbation schizophrenia within past 6 month Additional criterion may apply Is pregnant breastfeeding Had first lifetime psychotic episode less 1 year screening experience single lifetime psychotic episode Has know suspect intolerance , allergy , hypersensitivity olanzapine Has current pending legal charge potential incarceration Has positive drug screen opiates Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Alcohol Use Disorder</keyword>
	<keyword>ALKS 3831</keyword>
</DOC>